110 related articles for article (PubMed ID: 17046164)
1. Perspectives for targeted therapies in cancer of unknown primary site.
Pentheroudakis G; Pavlidis N
Cancer Treat Rev; 2006 Dec; 32(8):637-44. PubMed ID: 17046164
[TBL] [Abstract][Full Text] [Related]
2. Cancer of unknown primary site: missing primary or missing biology?
Pentheroudakis G; Briasoulis E; Pavlidis N
Oncologist; 2007 Apr; 12(4):418-25. PubMed ID: 17470684
[TBL] [Abstract][Full Text] [Related]
3. Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?
Massard C; Voigt JJ; Laplanche A; Culine S; Lortholary A; Bugat R; Theodore C; Priou F; Kaminsky MC; Lesimple T; Pivot X; Coudert B; Douillard JY; Merrouche Y; Fizazi K
Br J Cancer; 2007 Oct; 97(7):857-61. PubMed ID: 17876336
[TBL] [Abstract][Full Text] [Related]
4. Switching benchmarks in cancer of unknown primary: from autopsy to microarray.
Pentheroudakis G; Golfinopoulos V; Pavlidis N
Eur J Cancer; 2007 Sep; 43(14):2026-36. PubMed ID: 17698346
[TBL] [Abstract][Full Text] [Related]
5. [Treatment of cancer of unknown primary, today and future].
Shibata H
Gan To Kagaku Ryoho; 2009 Jun; 36(6):918-22. PubMed ID: 19542712
[TBL] [Abstract][Full Text] [Related]
6. Drug development of MET inhibitors: targeting oncogene addiction and expedience.
Comoglio PM; Giordano S; Trusolino L
Nat Rev Drug Discov; 2008 Jun; 7(6):504-16. PubMed ID: 18511928
[TBL] [Abstract][Full Text] [Related]
7. From gene testing to the bedside: workshop focuses on future strategies.
Goozner M
J Natl Cancer Inst; 2011 Aug; 103(15):1150-1. PubMed ID: 21768535
[No Abstract] [Full Text] [Related]
8. Forty years experience of treating cancer of unknown primary.
Pavlidis N
Acta Oncol; 2007; 46(5):592-601. PubMed ID: 17562435
[TBL] [Abstract][Full Text] [Related]
9. Cancers of unknown primary site.
Aziz M; Afroz N; Awasthi A; Hasan SA; Ahmad I
J Indian Med Assoc; 2011 Nov; 109(11):812-4. PubMed ID: 22666938
[TBL] [Abstract][Full Text] [Related]
10. Tumorigenic conversion of primary human esophageal epithelial cells using oncogene combinations in the absence of exogenous Ras.
Kim SH; Nakagawa H; Navaraj A; Naomoto Y; Klein-Szanto AJ; Rustgi AK; El-Deiry WS
Cancer Res; 2006 Nov; 66(21):10415-24. PubMed ID: 17079462
[TBL] [Abstract][Full Text] [Related]
11. Prospective gene signature study using microRNA to identify the tissue of origin in patients with carcinoma of unknown primary.
Varadhachary GR; Spector Y; Abbruzzese JL; Rosenwald S; Wang H; Aharonov R; Carlson HR; Cohen D; Karanth S; Macinskas J; Lenzi R; Chajut A; Edmonston TB; Raber MN
Clin Cancer Res; 2011 Jun; 17(12):4063-70. PubMed ID: 21531815
[TBL] [Abstract][Full Text] [Related]
12. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Introduction.
Bunn PA; Thatcher N
Oncologist; 2008; 13 Suppl 1():1-4. PubMed ID: 18263768
[TBL] [Abstract][Full Text] [Related]
13. Cancer of unknown primary site: evolving understanding and management of patients.
Greco FA
Clin Adv Hematol Oncol; 2012 Aug; 10(8):518-24. PubMed ID: 23073050
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy.
Weinstein IB; Joe AK
Nat Clin Pract Oncol; 2006 Aug; 3(8):448-57. PubMed ID: 16894390
[TBL] [Abstract][Full Text] [Related]
15. Role of hypoxia-inducible factor-1alpha as a cancer therapy target.
Patiar S; Harris AL
Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S61-75. PubMed ID: 17259560
[TBL] [Abstract][Full Text] [Related]
16. Exploring the biology of cancer of unknown primary: breakthroughs and drawbacks.
Kamposioras K; Pentheroudakis G; Pavlidis N
Eur J Clin Invest; 2013 May; 43(5):491-500. PubMed ID: 23480555
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor structural alterations in gastric cancer.
Moutinho C; Mateus AR; Milanezi F; Carneiro F; Seruca R; Suriano G
BMC Cancer; 2008 Jan; 8():10. PubMed ID: 18199332
[TBL] [Abstract][Full Text] [Related]
18. Molecular-targeted therapies: lessons from years of clinical development.
Rosa DD; Ismael G; Lago LD; Awada A
Cancer Treat Rev; 2008 Feb; 34(1):61-80. PubMed ID: 17826917
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of patients with cancer of an unknown primary site].
Enokida T; Ohyama Y
Gan To Kagaku Ryoho; 2012 May; 39(5):726-30. PubMed ID: 22584324
[TBL] [Abstract][Full Text] [Related]
20. Progress in refining the clinical management of cancer of unknown primary in the molecular era.
Rassy E; Pavlidis N
Nat Rev Clin Oncol; 2020 Sep; 17(9):541-554. PubMed ID: 32350398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
